Market news

The on-demand presentation will be available on September 11, 2026, at 7:00 A.M. (ET) BOCA RATON, Fla, Sept. 09, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced their attendance at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16 at the Lotte New York Palace Hotel in New York City. David Moss, Founder and Chief Executive Officer, will be ho

INmune Bio is significantly undervalued, with Ebstrocel for RDEB driving a compelling investment thesis. Read more on INMB stock here.

Orphan Drug Designation application and pre-MAA Scientific Advice package submitted for Ebstrocel™ in RDEBFilings support a planned EU MAA in Q1 2027; orphan designation, if granted and maintained through approval, may provide regulatory incentives and 10 years of market exclusivity BOCA RATON, Fla., Aug. 26, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) ("INmune Bio" or the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that it h

Motley Fool Press Release.

BOCA RATON, Fla., July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that on July 30, 2026, it received a research and development cash rebate from Australia of approximately $4.2 million. This rebate is in addition to approximately $0.4 million of rebate from the United Kingdom during June 2026. After adjusting second-quarter operating cash flows to exclude the approximately

Management to host conference call and webcast at 4:30 pm ET on that day BOCA RATON, Fla, July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced t that it will host a conference call on Thursday, August 6th, 2026 at 4:30pm EDT to discuss results for its quarter ended June 30, 2026 and to provide a corporate update. Conference Call Information To participate in this event, dial ap

Global Experts in MSC Clinical Translation to Advise Ebstrocel™ Regulatory and Clinical Development and Guide Expansion of CORDStrom Product Opportunities BOCA RATON, Fla., July 30, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced the formation of a Scientific Advisory Board ("SAB") to support the late-stage development of Ebstrocel™ for recessive dystrophic epidermolysis bullosa (“

Commercial-Ready Manufacturing Now Supports Planned Phase 3 Confirmation Trial, and US, EU and UK Regulatory Submissions for Future Commercial Supply. Company Expresses Support for MHRA Draft Rare Disease Therapies Regulatory Framework BOCA RATON, Fla, July 20, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced a significant manufacturing milestone for its CORDStrom™ platform. The Com

The study points to soluble TNF as a key biological link between head injury and Alzheimer’s disease and shows that selectively neutralizing it with XPro1595 prevents the injury-induced rise in amyloid pathology while improving early cognitive and pain-related outcomes. Boca Raton, FL, July 15, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a late-stage inflammation and immunology company, today announced the publication of a new peer-reviewed preclinical study in the Journal of Neuro

Advanced MRI analyses showed early treatment-related changes in white matter myelin integrity and cortical microstructure at Week 24, supporting biologic activity of selective soluble TNF inhibition. White matter myelin integrity demonstrated a statistically significant treatment difference at Week 24 in the modified intent-to-treat population (p < 0.01), with larger effects observed in patients selected using the company’s biomarker enrichment strategy. BOCA RATON, Fla., July 09, 2026 (GLOBE NE